Publication at First Faculty of Medicine |
2011
Abstract
In the clinical practice, the reason for switching from one anti-TNF therapy to another, e.g. from infliximab to adalimumab or vice versa, in patients with Crohn´s disease may not always be medical, e.g. loss of response, severe side effects or therapy intolerance, but it may also derive from the patient´s decision and preferences. The aim of the SWITCH study was to assess the outcomes in patients with Crohn´s disease in long-term clinical remission who had been switched from infliximab to adalimumab.